tldrdailynews.com logo
Tag

Syfovre

All articles tagged with #syfovre

business11 days ago

Biogen to Acquire Apellis, Expanding Immunology and Nephrology Footprint

Biogen will acquire Apellis for $41 per share in cash (about $5.6 billion) plus a contingent value right tied to SYFOVRE’s sales, adding two approved medicines—EMPAVELI and SYFOVRE—to Biogen’s growth portfolio and accelerating Biogen’s nephrology plans with Apellis’ team; 2025 combined net product revenue for EMPAVELI and SYFOVRE was $689 million and is expected to grow mid-to-high teens through 2028. Closing is anticipated in Q2 2026, financed by cash and borrowings with plans to de-leverage by 2027. Apellis’ US sales capabilities and nephrology expertise will bolster Biogen’s readiness for felzartamab in Phase 3, while Sobi retains EMPAVELI rights outside the U.S.; the CVR pays up to two $2-per-share amounts based on SYFOVRE sales thresholds and a possible $4-per-share payment in 2031 if higher sales are reached.

via Biogen|
#apellis#biogen#business
Apellis Investigates Needle Safety Concerns in Eye Disease Drug
health2 years ago

Apellis Investigates Needle Safety Concerns in Eye Disease Drug

Apellis Pharmaceuticals has identified internal structural variations in the needle used to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients. However, the company has not definitively linked the needle to the cases. Despite one additional case of the severe side effect, the overall frequency remains rare, leading to a 30% rise in Apellis shares as investors believe the safety crisis is abating.

via STAT|
#apellis-pharmaceuticals#eye-disease-drug#health
Apellis Pharmaceuticals Plunges on Safety Concerns for New Vision Loss Drug
health2 years ago

Apellis Pharmaceuticals Plunges on Safety Concerns for New Vision Loss Drug

Shares of Apellis Pharmaceuticals dropped by 20% after reports of rare but severe side effects emerged regarding their new drug, Syfovre, which is used to treat a common type of vision loss. The American Society of Retinal Specialists issued a letter to doctors warning of cases of eye inflammation, including occlusive retinal vasculitis, which can cause blindness. The side effects occurred one to two weeks after the first injection of Syfovre. Apellis stated that the real-world safety profile of the drug is consistent with clinical studies and they are investigating the cases. The drug has been approved for geographic atrophy, but concerns remain about its risk-benefit profile and potential for inflammation and infections.

via BioPharma Dive|
#apellis-pharmaceuticals#health#retinal-vasculitis
Revamping Eye Care for Syfovre Treatment of Geographic Atrophy
healthcare2 years ago

Revamping Eye Care for Syfovre Treatment of Geographic Atrophy

The recent FDA approval of Syfovre, a new injectable treatment for geographic atrophy, an advanced form of dry age-related macular degeneration, is making it more urgent than ever to address the issue of poor coordination between primary eye care providers and subspecialists. Optometrists and general ophthalmologists will play a critical role in identifying candidates for the new therapy, determining their eligibility, making appropriate referrals to retina specialists, and providing education about potential benefits. To ensure that eye care patients get the seamless care they need quickly and safely, it’s not just providers who need to change. We also need to improve the systems and processes that deliver patient care.

via STAT|
#eye-care#geographic-atrophy#healthcare